cordycepin has been researched along with Non-alcoholic Fatty Liver Disease in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 2 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gong, X; Li, T; Sha, L; Wan, R | 1 |
| Guo, J; Hu, S; Jiang, S; Lan, T; Li, H; Rong, X; Tian, S; Wang, L; Wang, W; Weng, Q; Xu, T; Yang, G; Yu, Y; Zhang, J; Zhang, Y; Zhu, Q | 1 |
| Hou, XJ; Li, J; Wang, FZ; Zhong, LP; Zhu, HB | 1 |
| Cheng, B; Li, T; Wen, L | 1 |
4 other study(ies) available for cordycepin and Non-alcoholic Fatty Liver Disease
| Article | Year |
|---|---|
Cordycepin attenuates high-fat diet-induced non-alcoholic fatty liver disease via down-regulation of lipid metabolism and inflammatory responses.
Topics: Animals; Anti-Inflammatory Agents; Deoxyadenosines; Diet, High-Fat; Disease Models, Animal; Down-Regulation; Hyperlipidemias; Hypolipidemic Agents; Inflammation Mediators; Lipids; Lipogenesis; Liver; Male; Mice, Inbred C57BL; Non-alcoholic Fatty Liver Disease; Obesity; Oxidation-Reduction | 2021 |
Cordycepin Ameliorates Nonalcoholic Steatohepatitis by Activation of the AMP-Activated Protein Kinase Signaling Pathway.
Topics: AMP-Activated Protein Kinases; Animals; Cell Line; Deoxyadenosines; Hepatocytes; Humans; Liver; Liver Cirrhosis; Mice; Non-alcoholic Fatty Liver Disease; Signal Transduction | 2021 |
[Protective effect and underlying mechanism of cordycepin on non-alcoholic fatty liver in ob/ob mice].
Topics: Administration, Oral; Animals; Blood Glucose; Body Weight; Deoxyadenosines; Inflammation; Insulin Resistance; Lipid Metabolism; Lipids; Lipogenesis; Male; Mice; Mice, Inbred C57BL; Mice, Obese; Non-alcoholic Fatty Liver Disease; Triglycerides | 2017 |
Cordycepin alleviates hepatic lipid accumulation by inducing protective autophagy via PKA/mTOR pathway.
Topics: Autophagy; Cell Survival; Cyclic AMP-Dependent Protein Kinases; Deoxyadenosines; Hep G2 Cells; Humans; Isoquinolines; Lipid Metabolism; Liver; Non-alcoholic Fatty Liver Disease; Palmitic Acid; Protective Agents; Signal Transduction; Sulfonamides; TOR Serine-Threonine Kinases; Triglycerides | 2019 |